Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2011
01/19/2011CN101088505B Nanometer breviscapine polymer particle preparation and its preparation process
01/19/2011CN101072773B Pyrrole derivatives having CRTH2 receptor antagonist activity
01/19/2011CN101057840B Application of Vam3 in preparing medicine for treating chronic obstructive disease of lung
01/19/2011CN101056644B Oral composition containing difructose anhydride
01/19/2011CN101052638B 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
01/19/2011CN101044151B Antiviral 4'-azido-nucleosides
01/19/2011CN101019851B Medium chain fatty acid liposome and its preparation
01/19/2011CN101014578B Triazole derivative or salt thereof
01/18/2011US7872153 Aliskiren hydrogen sulfate; crystal forms which are stable and easier to manage in the drying, filtration or granulation processes; used in conjuction with HMG-Co-A reductase inhibitor; angiotensin converting enzyme; calcium channel blocker; aldosterone synthase inhibitors; aldosterone antagonists
01/18/2011US7872152 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
01/18/2011US7872151 Inhibitors of α4 mediated cell adhesion
01/18/2011US7872147 Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
01/18/2011US7872142 Coumarin derivatives useful as TNFα inhibitors
01/18/2011US7872140 contacting (S)-omeprazole freebase or its sodium/potassium salt with inorganic or organic acid salt of the barium (barium chloride, barium sulfate, barium oxalate, barium acetate) in a suitable solvent ( methanol)in presence of a base ( NaOH) to form (S)-omeprazole barium; helicobacter infections
01/18/2011US7872139 Heteroaryl-ureas and their use as glucokinase activators
01/18/2011US7872134 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates
01/18/2011US7872133 N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-1,9-dihydrospiro[ beta-carboline-4,1'-cyclopropane]-2(3H)-carboxamide;affinity for mitochondrial benzodiazepine receptors preventive/therapeutic to stress-related diseases; irritable bowel syndrome; anxiolytic agents; nervous/respiratory system disorders;asthma
01/18/2011US7872129 Nitrogen compounds such as (6-(3-Methylaminopropyl)-2-(2-tri-fluoromethylphenyl)pyrimidin-4-yl)-(1H -pyrazolo(3,4-b)pyridin-3-yl)-amine, use as glycogen synthase kinase-3 (GSK-3) antagonists
01/18/2011US7872127 2-(4-(1-methyl-4-piperidinoxy)benzylamino)-2-methyl-propanamide; nervous system disorders; analgesics; anticonvulsants; sodium channel moderators; antidepressants, antiarrhythmics and for the treatment or prevention of diabetic neuropathy
01/18/2011US7872126 Tetrahydroquinoline derivatives and a process for preparing the same
01/18/2011US7872125 1-Methyl,3-((1,3-dichloro-phenyl)-carbonylamino-(1-carboxy- eth-1,2-ylene)-(1,4-phenylene)-)quinazolin-2,4-dione; inhibiting the adhesion of VCAM-1 (vascular cellular adhesion molecules-1) to alpha-4 integrin; antiinflammatory agents; cardiovascular disorders; multiple sclerosis; antiarthritic agent
01/18/2011US7872117 c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity
01/18/2011US7872112 comprising rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A),deoxyhypusine synthase (DHS) nucleic acids and polypeptides; human cytomegalovirus immediate-early promoter/enhancer
01/18/2011US7872052 2-(2-iodophenyl)-6,7-dimethoxybenzo[d][1,3]oxazin-4-one for treating atopic dermatitis, contact dermatitis, eczema, psoriasis, acne, epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus
01/18/2011US7872051 administering an effective amount of p-menthane-3,8-diol (PMD) to destroy, inactivate, or inhibit the growth or reproduction of a virus (influenza virus, A/Sydney/5/97 virus, Urbani SARS virus and HSV-1 virus); antiseptic and antifungal agent; PMD rich extract derived from lemon eucalyptus
01/18/2011US7872050 Stabilized compositions of volatile alkylating agents and methods of using thereof
01/18/2011US7872049 Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate
01/18/2011US7872048 administering to a patient a drug effective to inhibit a NCCa-ATPchannel, selected from LY397364, LY389382 an imidazoline derivative; glibenclamide, tolbutamide, gliclazide, and glimepiride a sulfonylurea derivative; channelrepaglinide, nateglinide, meglitinide a benzamido derivatives for treating edema
01/18/2011US7872047 idebenone octanoate; idebenone conjugated linoleate, idebenone linoleate; dematology; skin roughness, skin wrinkles, photodamaged skin, skin hyperpigmentation, skin irritation and skin inflammatory reaction
01/18/2011US7872046 Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
01/18/2011US7872045 Combination therapy for glaucoma treatment
01/18/2011US7872044 Inhibitors of chymase
01/18/2011US7872042 Use of tocotrienols for elevating IKBKAP gene expression and treating Familial Dysautonomia
01/18/2011US7872041 administering to the patient a compound selected from rotigotine, a physiologically acceptable salt of rotigotine, and a rotigotine prodrug, wherein the compound is administered to provide a rotigotine dosage of 0.05 mg to approximately 50 mg per day
01/18/2011US7872040 An alpha 2 receptor blocker and a vasodilator comprising an melatonin derivative as an active ingredient; drugs; foods;simpler than yohimbine and has a similar effect; adrenergic blocking agents; side effect reduction
01/18/2011US7872039 3-aminoindazoles
01/18/2011US7872037 (4-Isopropyl-benzyl)-[1-(4-methoxy-phenyl)-1H-benzimidazol-5-yl]-amine; potent inhibitor of viral infection mediated by envelopes of the New World arenaviruses Guanarito & Tacaribe; compounds may have utility for treatment of arenavirus diseases other than Lassa fever;hemorrhagic fevers; vaccines
01/18/2011US7872035 Angiotensin II antagonists
01/18/2011US7872034 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
01/18/2011US7872033 N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants
01/18/2011US7872032 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
01/18/2011US7872031 such as 3-(1-(2,3-difluorophenyl)-1H-tetrazol-5-yl)-5-(4-(4-methylpiperazin-1-yl) phenyl)pyridin-2-amine, used as anticarcinogenic agents or for the treatment of atherosclerosis and lung fibrosis
01/18/2011US7872030 Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
01/18/2011US7872029 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
01/18/2011US7872028 such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders
01/18/2011US7872027 Low molecular weight Myc-max inhibitors
01/18/2011US7872026 retinoic acid receptor (RAR) activators such as 4'-(4-Isopropylaminobutoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)biphenyl-4-carboxylic acid, suited for administration in human or veterinary medicine; dermatology
01/18/2011US7872025 Optically active isomers of ketotifen and therapeutically active metabolites thereof
01/18/2011US7872024 Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
01/18/2011US7872023 Kappa opioid receptor ligands
01/18/2011US7872022 Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
01/18/2011US7872021 Liver X receptors (LXR) modulators such as 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-methoxy-N-(2-phenyl ethyl)-2,3-dihydro-1H-)indole-2-carboxamide, used for the treatment of atherosclerosis, dyslipidemia, obesity, diabetes, hypercholesterolemia, neurodegenerative diseases and inflammatory diseases
01/18/2011US7872020 TGF-β inhibitors
01/18/2011US7872019 Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
01/18/2011US7872018 Compounds and methods for kinase modulation, and indications therefor
01/18/2011US7872017 such as 5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole, having nicotinic receptors modualtory activity, used for the treatment of attention deficit disorder, senile dementia, Down's syndrome, amyotrophic lateral sclerosis, Huntington's, Pick's and Alzheimer's disease
01/18/2011US7872016 Method for treating skeletal disorders resulting from FGFR malfunction
01/18/2011US7872015 methods for detection, characterization, treatment of neurodegenerative pathologies and identification or screening of compounds such as etazolate in aforementioned pathologies; role of phosphodiesterase 4B, peripheral benzodiazepine receptor (PBR) and GABA receptors of type GABA(A) in these pathologies
01/18/2011US7872014 Anaplastic lymphoma kinase modulators and methods of use
01/18/2011US7872013 opiod and/or N-methylaspartic acid receptor modulators, used for the treatment and/or management of pain, neurodegenerative diseases, drug abuse and dependence, vision defects, or as muscle relaxants, antitussive and anxiolytic agents
01/18/2011US7872012 Pyrimidinone compounds and preparation and use thereof
01/18/2011US7872011 Inhibition of phosphoinositide 3-kinase β
01/18/2011US7872010 Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors
01/18/2011US7872009 Beta-Secretase inhibitors such as 1-cyclopentyl-N-((2S,3R)-4-((S)-6-ethyl-2,2-spirocyclobutylchroman-4-ylamino)-3-hydroxy-1-(thiophen-3-yl)butan-2-yl)-6-oxo-5-(2-oxopyrrolidin-1-yl)-1,6-dihydropyridine-3-carboxamide, useful for the treatment of Alzheimer's disease
01/18/2011US7872008 Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
01/18/2011US7872007 reacting N-hydroxymorpholine with 2-cyclohexen-1-one, in the presence of an oxidizer, to obtaining an isoxazolidine chemical intermediate, then converting isoxazolidine intermediate into 2-(4-hydroxy-3-morpholinyl)-2-cyclohexenone
01/18/2011US7872006 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methoxy-3-[N-(1-azacycloheptyl)-carbamoyl]-1H-pyrazole, useful for treatment of nervous system disorders
01/18/2011US7872005 2-substituted heteroaryl compounds
01/18/2011US7872004 Therapy, propjylxis of aids; side effect reduction
01/18/2011US7872003 Anticancer agents; kinase inhibitor; immunotherapy; viricides; antiinflammatory agents
01/18/2011US7872002 Therapeutic pyrazoloquinoline derivatives
01/18/2011US7872001 Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
01/18/2011US7872000 Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
01/18/2011US7871999 Substituted thiazoles and their use for producing drugs
01/18/2011US7871998 Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
01/18/2011US7871997 Potency against gram-positive bacteria, methicillin-resistant Staphylococci aureus (MRSA), methicillin-resistant Staphylococci epidermitis (MRSE).
01/18/2011US7871996 Contacting nitric oxide synthase with a corrin derivative; binding nitric oxide synthase but not nitric oxide; inflammatory, neurological disease, conjunctivitis, cystitis, inflammatory bowel disease, nephritis, glomerulonephritis, hepatitis, arteritis, vasculitis, cerebritis, vaginitis
01/18/2011US7871995 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
01/18/2011US7871994 at least one ingestion period preceding the permanent administration of hormone daily units has an ingestion pause in which either no daily units or units with a much lower hormone content is given
01/18/2011US7871993 Methyl ethyl ketone solvate or an ethyl acetate solvate; improved chemical and physical stability over the amorphous form, and forms with low crystallinity, improved hygroscopicity, bulk properties, and/or flowability; storage stability
01/18/2011US7871992 antiallergen, viricide, herbicide, autoimmune diseases; screening procedure for the identification of enzymes GcpE and LytB inhibitor; 4-hydroxy-3-methyl-2-butenyl 1-pyrophosphate; precursor of higher isoprenoids in 2-methyl-D-erythritol pathway (MEP)
01/18/2011US7871991 Phosphonate analogs of HIV inhibitor compounds
01/18/2011US7871987 Ester derivatives of ascorbic and 2-keto acid saccharides
01/18/2011US7871985 Compositions and methods for inhibiting expression of factor VII gene
01/18/2011US7871983 For therapy and prophylaxis of ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia
01/18/2011US7871982 potent activity against resistant pneumococci
01/18/2011US7871816 for preparing a vaccine which contains one or more than two genes among pgs B, pgs C and pgs A encoding poly- gamma -glutamate synthetase complex and genes selected from human papilloma virus (HPV) E6 and HPV E7 antigen protein associated with tumor induction; genital wash
01/18/2011US7871767 Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic applications
01/18/2011US7871765 Composition having antitumor effect
01/18/2011US7871763 gene expression; probes, primers, antibodies
01/18/2011US7871649 Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
01/18/2011US7871644 Mixture of drug, aminoacrylate polymer and acid
01/18/2011US7871635 comprising a cosmetically acceptable medium and a compound N-( omega -undecylenoyl) phenylalanine; inactivates adenylate cyclase and has an affinity for the melocytic specific hormone ( alpha -MSH)
01/18/2011US7871631 Inhibit inflammation for long periods without accompanying serious side effects in the drug therapy to patients with inflammatory bowel syndrome
01/18/2011US7871620 Immunoliposomes that optimize internationalization into target cells
01/18/2011US7871602 1,4-bis[isobutylamino]2,3-dihydroxy butane; antiseptic and disinfectant; preventing microbial contamination; multi-functional component for contact lens solution and multi-dose ophthalmic compositions
01/18/2011US7871599 shampoo or conditioner suitable for topical application in style hair and in particular to lengthening, reducing the volume and increasing the high humidity style retention of the hair
01/18/2011US7871597 Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis
01/18/2011US7871402 System with a reservoir for perfusion management
01/18/2011CA2618636C Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands